Multiple Myeloma Market
Multiple Myeloma Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (Smoldering (indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma); By Treatment (Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-Modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, Surgery); By Diagnosis (Blood & Urine Tests, X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT/CAT) Scan, Positron Emission Tomography (PET)/ PET-CT Scan, Bone Marrow Aspiration & Biopsy, Fat Pad Aspirate, Biomarker Testing of the Tumor); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
- Published Date: October 2023
- Report ID: BWC23812
- Available Format: PDF
- Page: 400
Report Overview
The rising incidence of multiple myeloma globally and increasing advancements in targeted drugs are projected to propel the expansion of the global multiple myeloma market during the forecast period between 2023 and 2029
Global Multiple Myeloma Market - Industry Trends & Forecast Report, 2029
Global multiple myeloma market size was estimated at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, the size of global multiple myeloma market is projected to grow at a CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include an increasing adoption of microRNA therapies. These innovative therapeutic approaches harness the potential of microRNAs to modulate gene expression and regulate various cellular processes. The development of targeted microRNA therapies offers the prospect of more precise and individualized treatments for multiple myeloma. Also, the rise of advanced biomedicine platforms plays a pivotal role in driving the growth of the multiple myeloma market. These platforms encompass a diverse array of technologies and methodologies that facilitate the comprehension of the molecular underpinnings of the disease, the discovery of novel therapeutic targets, and the formulation of more efficacious treatment strategies. By leveraging these advanced platforms, researchers and healthcare practitioners can gain deeper insights into Multiple Myeloma and advance the development of groundbreaking therapeutic interventions.
Global Multiple Myeloma Market – Overview
The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by factors such as medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.
Global Multiple Myeloma Market
Growth Drivers
Rising Incidence of Multiple Myeloma Globally
The relentless global rise in multiple myeloma diagnoses fuels the exponential growth of the global multiple myeloma market. This surge not only underscores the pressing need for improved treatments but also propels proactive measures within the pharmaceutical and healthcare sectors. The escalating incidence drives intensified research, yielding innovative therapies, cutting-edge pharmaceuticals, and groundbreaking treatment approaches. Pharmaceutical enterprises are investing significantly in tailored medications for this intricate malignancy, while healthcare providers are diligently working to enhance patient access to these transformative innovations. These collective efforts synergize with the alarming statistics: an estimated 35,730 diagnoses in the United States in 2023 and approximately 176,404 global cases diagnosed in 2020. These figures underscore the substantial burden this disease places on both a national and global scale, emphasizing the urgent need for advanced targeted drugs and therapies within the global multiple myeloma market.
Restraints
High Treatment Costs
The global multiple myeloma market encounters a significant growth constraint in the form of high treatment costs. The complex nature of multiple myeloma necessitates multifaceted treatment approaches, including targeted drugs, immunotherapies, and stem cell transplants, all of which can be financially burdensome for patients and healthcare systems. These elevated treatment expenses pose challenges in terms of patient access to cutting-edge therapies and often result in financial strain on individuals and their families. Furthermore, the financial burden of multiple myeloma treatment can limit market expansion by curbing investment in research and development. Mitigating the cost barriers while maintaining treatment quality is essential for realizing the full potential of the global multiple myeloma market.
Impact of COVID-19 on Global Multiple Myeloma Market
COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The global multiple myeloma market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.
Global Multiple Myeloma Market
Segmental Coverage
Global Multiple Myeloma Market – By Type
Based on type, the global multiple myeloma market is bifurcated into Smoldering (indolent) Multiple Myeloma and Active (symptomatic) Multiple Myeloma segments. The active (symptomatic) multiple myeloma segment is expected to hold a higher share in the global multiple myeloma market during the forecast period by type. This is primarily because active multiple myeloma requires immediate and often more aggressive medical intervention, including chemotherapy, targeted drugs, and stem cell transplants, making it a higher priority for treatment compared to asymptomatic myeloma. Additionally, the increasing incidence of symptomatic cases underscores the growing demand for advanced treatments, further driving the prominence of the active myeloma segment in the market.
Global Multiple Myeloma Market – By Treatment
On the basis of treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-Modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs like Thalomid, Revlimid, and pomalyst being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.
Global Multiple Myeloma Market – By Diagnosis
Based on diagnosis, the global multiple myeloma market is divided into Blood and urine tests, X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT or CAT) Scan, Positron Emission Tomography (PET) or PET-CT Scan, Bone Marrow Aspiration & Biopsy, Fat Pad Aspirate, and Biomarker Testing of the tumor segments.
Global Multiple Myeloma Market – By Region
The in-depth research report on the global multiple myeloma market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa. North America is poised to play a significant role in the multiple myeloma market during the forecast period, driven by several factors. These include the growing incidence of multiple myeloma, increased efforts by pharmaceutical companies in developing effective treatments, rising healthcare expenditure, substantial healthcare investments, and the presence of key market players in the region. The rising prevalence of multiple myeloma is a primary catalyst for market expansion. Also, according to ACS, the lifetime risk of developing multiple myeloma in the U.S. stands at 1 in 132 (0.76%). Similarly, in Canada, the Canadian Cancer Society estimated around 4,000 new cases of multiple myeloma (MM) for 2022. This substantial disease burden underscores the demand for effective treatments, thereby fueling market growth. Notably, the introduction of various awareness programs and campaigns aimed at increasing public understanding of multiple myeloma is contributing to market expansion. These initiatives are expected to enhance public knowledge about the condition and further drive market growth during the forecast period
Competitive Landscape
Major players operating in the global multiple myeloma market include Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
Recent Developments
-
In December 2022 - Kite, a subsidiary of Gilead, established a global strategic collaboration with Aecellex for the collaborative advancement and marketing of CART-ddBCMA, a T-cell therapy designed for the treatment of individuals with relapsed or refractory multiple myeloma. Furthermore, the CART-ddBCMA therapy is currently undergoing Phase I clinical evaluation. As part of this partnership, Arcellx will provide an initial payment of USD 225 million to Kite.
Scope of the Report
Attributes |
Details |
Years Considered |
Historical Data – 2019–2022 |
Base Year – 2022 |
|
Estimated Year – 2023 |
|
Forecast Period – 2023–2029 |
|
Facts Covered |
Revenue in USD Billion |
Market Coverage |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Product/ Service Segmentation |
Type, Treatment, Diagnosis, Region |
Key Players |
Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, Roche Group. |
By Type
-
Smoldering (indolent) Multiple Myeloma
-
Active (symptomatic) Multiple Myeloma
By Treatment
-
Chemotherapy
-
Targeted Therapy
-
Immunomodulatory Drugs
-
Steroids
-
Bone-modifying Drugs
-
Immunotherapy
-
Bone Marrow/Stem Cell Transplantation
-
Radiation Therapy
-
Surgery
By Diagnosis
-
Blood & Urine Tests
-
X-ray
-
Magnetic Resonance Imaging (MRI)
-
Computed Tomography (CT/CAT) Scan
-
Positron Emission Tomography (PET)/PET-CT Scan
-
Bone marrow Aspiration & Biopsy
-
Fat Pad Aspirate
-
Biomarker Testing of the Tumor
By Region
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East and Africa
- Research Framework
- Research Objective
- Product Overview
- Market Segmentation
- Executive Summary
- Global Multiple Myeloma Market Insights
- Industry Value Chain Analysis
- DROC Analysis
- Growth Drivers
- The rising incidence of Multiple Myeloma globally
- Advancements in targeted drugs
- Restraints
- High treatment costs
- Stringent regulatory requirements
- Opportunities
- Emerging markets
- Personalized medicine
- Challenges
- Competition
- Drug resistance
- Growth Drivers
- Technological Advancements/Recent Developments
- Regulatory Framework
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Global Multiple Myeloma Market Overview
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share and Forecast
- By Type
- Smoldering (indolent) Multiple Myeloma
- Active (symptomatic) Multiple Myeloma
- By Treatment
- Chemotherapy
- Targeted Therapy
- Immunomodulatory Drugs
- Steroids
- Bone-modifying Drugs
- Immunotherapy
- Bone Marrow/Stem Cell Transplantation
- Radiation Therapy
- Surgery
- Others
- By Diagnosis
- Blood & Urine Tests
- X-ray
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT or CAT) Scan
- Positron Emission Tomography (PET) or PET-CT Scan
- Bone Marrow Aspiration and Biopsy
- Fat Pad Aspirate
- Biomarker Testing of the Tumor
- Others
- By Region
- North America
- Europe
- Asia Pacific (APAC)
- Latin America (LATAM)
- Middle East and Africa (MEA)
- By Type
- Market Size & Forecast, 2019–2029
- North America Multiple Myeloma Market
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By Diagnosis
- By Country
- United States
- By Type
- By Treatment
- By Diagnosis
- Canada
- By Type
- By Treatment
- By Diagnosis
- United States
- Market Size & Forecast, 2019–2029
- Europe Multiple Myeloma Market
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By Diagnosis
- By Country
- Germany
- By Type
- By Treatment
- By Diagnosis
- United Kingdom
- By Type
- By Treatment
- By Diagnosis
- Italy
- By Type
- By Treatment
- By Diagnosis
- France
- By Type
- By Treatment
- By Diagnosis
- Spain
- By Type
- By Treatment
- By Diagnosis
- Belgium
- By Type
- By Treatment
- By Diagnosis
- Russia
- By Type
- By Treatment
- By Diagnosis
- The Netherlands
- By Type
- By Treatment
- By Diagnosis
- Rest of Europe
- By Type
- By Treatment
- By Diagnosis
- Germany
- Market Size & Forecast, 2019–2029
- Asia-Pacific Multiple Myeloma Market
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By Diagnosis
- By Country
- China
- By Type
- By Treatment
- By Diagnosis
- India
- By Type
- By Treatment
- By Diagnosis
- Japan
- By Type
- By Treatment
- By Diagnosis
- South Korea
- By Type
- By Treatment
- By Diagnosis
- Australia & New Zealand
- By Type
- By Treatment
- By Diagnosis
- Indonesia
- By Type
- By Treatment
- By Diagnosis
- Malaysia
- By Type
- By Treatment
- By Diagnosis
- Singapore
- By Type
- By Treatment
- By Diagnosis
- Vietnam
- By Type
- By Treatment
- By Diagnosis
- Rest of APAC
- By Type
- By Treatment
- By Diagnosis
- China
- Market Size & Forecast, 2019–2029
- Latin America Multiple Myeloma Market
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By Diagnosis
- By Country
- Brazil
- By Type
- By Treatment
- By Diagnosis
- Mexico
- By Type
- By Treatment
- By Diagnosis
- Argentina
- By Type
- By Treatment
- By Diagnosis
- Peru
- By Type
- By Treatment
- By Diagnosis
- Rest of LATAM
- By Type
- By Treatment
- By Diagnosis
- Brazil
- Market Size & Forecast, 2019–2029
- Middle East & Africa Multiple Myeloma Market
- Market Size & Forecast, 2019–2029
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By Diagnosis
- By Country
- Saudi Arabia
- By Type
- By Treatment
- By Diagnosis
- UAE
- By Type
- By Treatment
- By Diagnosis
- Qatar
- By Type
- By Treatment
- By Diagnosis
- Kuwait
- By Type
- By Treatment
- By Diagnosis
- South Africa
- By Type
- By Treatment
- By Diagnosis
- Nigeria
- By Type
- By Treatment
- By Diagnosis
- Algeria
- By Type
- By Treatment
- By Diagnosis
- Rest of MEA
- By Type
- By Treatment
- By Diagnosis
- Saudi Arabia
- Market Size & Forecast, 2019–2029
- Competitive Landscape
- List of Key Players and Their Offerings
- Global Multiple Myeloma Market Share Analysis, 2022
- Competitive Benchmarking, By Operating Parameters
- Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
- Impact of Covid-19 on Global Multiple Myeloma Market
- Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc.
- AstraZeneca
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd
- ONO Pharmaceutical Co., Ltd
- Takeda Pharmaceutical Company Ltd
- Roche Group
- Other Prominent Players
- Key Strategic Recommendations
- Research Methodology
- Qualitative Research
- Primary & Secondary Research
- Quantitative Research
- Market Breakdown & Data Triangulation
- Secondary Research
- Primary Research
- Breakdown of Primary Research Respondents, By Region
- Assumptions & Limitations
- Qualitative Research
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
Figures
Figure 1 Global Multiple Myeloma Segmentation
Figure 2 Global Multiple Myeloma Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2022
Figure 4 Global Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 5 Global Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 6 Global Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 7 Global Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 8 Global Multiple Myeloma Market Share, By Region, By Value, 2019–2029
Figure 9 North America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 10 North America Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 11 North America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 12 North America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 13 North America Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Figure 14 United States Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 15 United States Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 16 United States Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 17 United States Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 18 Canada Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 19 Canada Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 20 Canada Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 21 Canada Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 22 Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 23 Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 24 Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 25 Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 26 Europe Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Figure 27 Germany Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 28 Germany Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 29 Germany Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 30 Germany Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 31 United Kingdom Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 32 United Kingdom Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 33 United Kingdom Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 34 United Kingdom Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 35 Italy Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 36 Italy Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 37 Italy Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 38 Italy Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 39 France Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 40 France Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 41 France Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 42 France Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 43 Spain Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 44 Spain Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 45 Spain Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 46 Spain Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 47 Belgium Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 48 Belgium Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 49 Belgium Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 50 Belgium Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 51 Russia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 52 Russia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 53 Russia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 54 Russia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 55 The Netherlands Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 56 The Netherlands Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 57 The Netherlands Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 58 The Netherlands Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 59 Rest of Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 60 Rest of Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 61 Rest of Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 62 Rest of Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 63 Asia-Pacific Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 64 Asia-Pacific Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 65 Asia-Pacific Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 66 Asia-Pacific Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 67 Asia-Pacific Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Figure 68 China Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 69 China Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 70 China Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 71 China Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 72 India Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 73 India Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 74 India Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 75 India Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 76 Japan Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 77 Japan Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 78 Japan Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 79 Japan Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 80 South Korea Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 81 South Korea Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 82 South Korea Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 83 South Korea Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 84 Australia & New Zealand Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 85 Australia & New Zealand Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 86 Australia & New Zealand Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 87 Australia & New Zealand Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 88 Indonesia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 89 Indonesia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 90 Indonesia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 91 Indonesia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 92 Malaysia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 93 Malaysia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 94 Malaysia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 95 Malaysia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 96 Singapore Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 97 Singapore Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 98 Singapore Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 99 Singapore Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 100 Vietnam Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 101 Vietnam Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 102 Vietnam Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 103 Vietnam Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 104 Rest of APAC Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 105 Rest of APAC Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 106 Rest of APAC Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 107 Rest of APAC Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 108 Latin America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 109 Latin America Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 110 Latin America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 111 Latin America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 112 Latin America Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Figure 113 Brazil Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 114 Brazil Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 115 Brazil Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 116 Brazil Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 117 Mexico Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 118 Mexico Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 119 Mexico Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 120 Mexico Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 121 Argentina Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 122 Argentina Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 123 Argentina Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 124 Argentina Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 125 Peru Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 126 Peru Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 127 Peru Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 128 Peru Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 129 Rest of LATAM Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 130 Rest of LATAM Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 131 Rest of LATAM Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 132 Rest of LATAM Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 133 Middle East & Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 134 Middle East & Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 135 Middle East & Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 136 Middle East & Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 137 Middle East & Africa Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Figure 138 Saudi Arabia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 139 Saudi Arabia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 140 Saudi Arabia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 141 Saudi Arabia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 142 UAE Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 143 UAE Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 144 UAE Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 145 UAE Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 146 Qatar Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 147 Qatar Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 148 Qatar Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 149 Qatar Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 150 Kuwait Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 151 Kuwait Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 152 Kuwait Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 153 Kuwait Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 154 South Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 155 South Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 156 South Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 157 South Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 158 Nigeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 159 Nigeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 160 Nigeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 161 Nigeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 162 Algeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 163 Algeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 164 Algeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 165 Algeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Figure 166 Rest of MEA Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Figure 167 Rest of MEA Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Figure 168 Rest of MEA Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Figure 169 Rest of MEA Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
List of Tables
Table 1 Global Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 2 Global Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 3 Global Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 4 Global Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 5 Global Multiple Myeloma Market Share, By Region, By Value, 2019–2029
Table 6 North America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 7 North America Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 8 North America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 9 North America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 10 North America Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Table 11 United States Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 12 United States Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 13 United States Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 14 United States Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 15 Canada Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 16 Canada Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 17 Canada Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 18 Canada Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 19 Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 20 Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 21 Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 22 Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 23 Europe Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Table 24 Germany Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 25 Germany Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 26 Germany Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 27 Germany Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 28 United Kingdom Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 29 United Kingdom Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 30 United Kingdom Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 31 United Kingdom Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 32 Italy Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 33 Italy Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 34 Italy Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 35 Italy Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 36 France Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 37 France Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 38 France Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 39 France Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 40 Spain Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 41 Spain Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 42 Spain Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 43 Spain Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 44 Belgium Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 45 Belgium Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 46 Belgium Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 47 Belgium Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 48 Russia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 49 Russia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 50 Russia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 51 Russia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 52 The Netherlands Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 53 The Netherlands Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 54 The Netherlands Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 55 The Netherlands Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 56 Rest of Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 57 Rest of Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 58 Rest of Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 59 Rest of Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 60 Asia-Pacific Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 61 Asia-Pacific Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 62 Asia-Pacific Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 63 Asia-Pacific Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 64 Asia-Pacific Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Table 65 China Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 66 China Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 67 China Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 68 China Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 69 India Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 70 India Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 71 India Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 72 India Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 73 Japan Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 74 Japan Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 75 Japan Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 76 Japan Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 77 South Korea Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 78 South Korea Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 79 South Korea Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 80 South Korea Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 81 Australia & New Zealand Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 82 Australia & New Zealand Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 83 Australia & New Zealand Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 84 Australia & New Zealand Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 85 Indonesia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 86 Indonesia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 87 Indonesia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 88 Indonesia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 89 Malaysia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 90 Malaysia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 91 Malaysia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 92 Malaysia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 93 Singapore Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 94 Singapore Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 95 Singapore Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 96 Singapore Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 97 Vietnam Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 98 Vietnam Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 99 Vietnam Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 100 Vietnam Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 101 Rest of APAC Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 102 Rest of APAC Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 103 Rest of APAC Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 104 Rest of APAC Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 105 Latin America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 106 Latin America Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 107 Latin America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 108 Latin America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 109 Latin America Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Table 110 Brazil Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 111 Brazil Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 112 Brazil Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 113 Brazil Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 114 Mexico Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 115 Mexico Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 116 Mexico Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 117 Mexico Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 118 Argentina Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 119 Argentina Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 120 Argentina Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 121 Argentina Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 122 Peru Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 123 Peru Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 124 Peru Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 125 Peru Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 126 Rest of LATAM Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 127 Rest of LATAM Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 128 Rest of LATAM Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 129 Rest of LATAM Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 130 Middle East & Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 131 Middle East & Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 132 Middle East & Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 133 Middle East & Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 134 Middle East & Africa Multiple Myeloma Market Share, By Country, By Value, 2019–2029
Table 135 Saudi Arabia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 136 Saudi Arabia Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 137 Saudi Arabia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 138 Saudi Arabia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 139 UAE Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 140 UAE Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 141 UAE Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 142 UAE Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 143 Qatar Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 144 Qatar Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 145 Qatar Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 146 Qatar Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 147 Kuwait Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 148 Kuwait Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 149 Kuwait Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 150 Kuwait Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 151 South Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 152 South Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 153 South Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 154 South Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 155 Nigeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 156 Nigeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 157 Nigeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 158 Nigeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 159 Algeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 160 Algeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 161 Algeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 162 Algeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 163 Rest of MEA Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029
Table 164 Rest of MEA Multiple Myeloma Market Share, By Type, By Value, 2019–2029
Table 165 Rest of MEA Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029
Table 166 Rest of MEA Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029
Table 167 Sanofi Company Overview
Table 168 Sanofi Financial Overview
Table 169 Pfizer Inc. Company Overview
Table 170 Pfizer Inc. Financial Overview
Table 171 GlaxoSmithKline plc Company Overview
Table 172 GlaxoSmithKline plc Financial Overview
Table 173 Novartis AG Company Overview
Table 174 Novartis AG Financial Overview
Table 175 Bayer AG Company Overview
Table 176 Bayer AG Financial Overview
Table 177 Eli Lilly and Company Overview
Table 178 Eli Lilly and Company Financial Overview
Table 179 Merck & Co., Inc. Company Overview
Table 180 Merck & Co., Inc. Financial Overview
Table 181 AstraZeneca Company Overview
Table 182 AstraZeneca Financial Overview
Table 183 Bristol-Myers Squibb Company Overview
Table 184 Bristol-Myers Squibb Company Financial Overview
Table 185 AbbVie Inc. Company Overview
Table 186 AbbVie Inc. Financial Overview
Table 187 Teva Pharmaceutical Industries Ltd. Company Overview
Table 188 Teva Pharmaceutical Industries Ltd. Financial Overview
Table 189 ONO Pharmaceutical Co., Ltd. Company Overview
Table 190 ONO Pharmaceutical Co., Ltd. Financial Overview
Table 191 Takeda Pharmaceutical Company Ltd. Company Overview
Table 192 Takeda Pharmaceutical Company Ltd. Financial Overview
Table 193 Roche Group Company Overview
Table 194 Roche Group Financial Overview
Market Segmentation
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
Frequently Asked Questions (FAQs):
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.